← Eichor
Study identifier: NCT04515459 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of Pre-operative Prehabilitation in Patients With Limb Sarcoma

Condition: Sarcoma  ·  Sponsor: Institut Claudius Regaud

PhasePhase 2
Planned participants53
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

This Phase II feasibility study, prospective, interventional, monocentric aiming to assess the interest of pre-operative rehabilitation in patients treated for bone or soft-tissue sarcoma of the limbs. This protocol will be based on the realisation of a surgical prehabilitation program adapted to the patient. This strategy will involve a team of several health professionals: rehabilitation doctor, physiotherapist, occupational therapist, specialised nurse, dietician and adapted physical activity teacher. The aim of an adapted surgical prehabilitation program is to improve the functional recovery of the treated limb and the patient's autonomy after surgery. Each patient will be followed until 24 months post surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Dimitri GANGLOFF  ·  05 31 15 53 58  ·  gangloff.dimitri@iuct-oncopole.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Institut Universitaire du Cancer de Toulouse - OncopoleToulouse, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04515459